Altimmune posts mixed results for incretin drug in MASH; stock is halved
Altimmune said its experimental therapy for a serious fatty liver disease hit one key endpoint but not the other in a Phase 2b study. The biotech’s shares {$ALT} tanked after the ...
Altimmune said its experimental therapy for a serious fatty liver disease hit one key endpoint but not the other in a Phase 2b study.
The biotech’s shares {$ALT} tanked after the ...
